Purpose: In patients with epidermal growth factor receptor (EGFR) mutant lung
adenocarcinoma, treatment with erlotinib or gefitinib is associated with a 75% radiographic …

Preclinical data suggest that combined EGF receptor (EGFR) targeting with an EGFR
tyrosine kinase inhibitor and an anti-EGFR monoclonal antibody may be superior over …

Introduction: Patients with epidermal growth factor receptor (EGFR) mutation positive non–
small-cell lung cancer exhibited marked response to gefitinib or erlotinib. In most cases …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Fig 1. Effects of L747S and T790M in the sensitivity of L858R-EGFR to gefitinib and
erlotinib.(A) Ba/F3 cells stably containing constructs with the L858R, L858R-L747S or …

7525^ Background: Despite initial responses to reversible epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors,(erlotinib or gefitinib), all non-small cell lung cancer …

Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …

Background Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and
treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired …

Lung cancer is the most common cancer in the world. Despite modern advancements in
surgeries, chemotherapies, and radiotherapies over the past few years, lung cancer still …

Although the EGF receptor tyrosine kinase inhibitors (EGFR-TKI) erlotinib and gefitinib have
shown dramatic effects against EGFR mutant lung cancer, patients become resistant by …